← All trials
NCT04116502
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2019
- Primary completion
- Aug 1, 2026
- Completion date
- Feb 1, 2028
- First posted
- —
- Last posted
- —
- Enrollment
- 586
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BirminghamLead sponsor
- University of LondonOverall official - principal investigator
- University of ParisOverall official - principal investigator
- MPN VoiceCollaborator
- National Cancer Institute, FranceCollaborator
- NovartisCollaborator
- University of LondonOfficial
- University of ParisOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.